Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 10 November 2020
    HitGen Licenses Its Trk/ROS1 Inhibitor HG030 to Baiyunshan for Development and Commercialisation in China
    CHENGDU, CHINA, November 10 - HitGen Inc. (HitGen, 688222.SH) announces it has entered into a collaboration and licensing agreement with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd (Baiyunshan, 600332.SH/00874.HK) to develop and commercialise its HG030 programme in mainland China. Baiyunshan is a publically listed company in Shanghai and Hong Kong engaged in the pharmaceutical and healthcare industry. HG030 is a novel inhibitor for Trk/ROS1 discovered by HitGen, which received IND approval from China’s National Medical Products Administration (NMPA) in March 2020, and is entering Phase I clinical trial in China for patients with NTRK/ ROS1 gene fusion-positive cancers.
  • 12 October 2020
    HitGen to acquire Vernalis, a leader in structure-based drug discovery
    CHENGDU, CHINA - HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research. The acquisition is for the entire issued share capital of Vernalis (R&D) Limited, for $25M in cash. The closing of this transaction is subject to customary conditions and approvals, expected to complete before the end of 2020.
  • 26 August 2020
    HitGen and Almirall announce achievement of milestone in their strategic collaboration
    Chengdu, China, August 26, 2020 HitGen Inc. (688222.SH) announced that the company has achieved a milestone in their strategic collaboration with Almirall to develop a novel class of drugs. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing more than 500 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds.
  • 06 July 2020
    HitGen and Morphic Extend Drug Discovery Research Collaboration
    Chengdu, China, July 6, 2020 – HitGen Inc. (HitGen, 688222.SH) announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compounds that were exclusively licensed to Morphic.
  • 08 June 2020
    HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration
    CHENGDU, China, June 8, 2020 -- HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with Evotec SE to identify small molecule leads against targets of interest to Evotec SE in the field of anti-infectives. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to Evotec SE. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and license fee from Evotec SE.
  • 26 May 2020
    Oncodesign and HitGen announce a strategic partnership in Integrated Drug Discovery Services (IDDS)
    Dijon (France) and Chengdu (China), May 25, 2020, 6:00pm (France)-ONCODESIGN (ALONC – FR0011766229) and HITGEN (688222.SH) today announced the start of a worldwide strategic alliance in Integrated Drug Discovery Services for the identification and progression of new chemical entities, spanning from Hit finding up to preparation of the Investigational New Drug filing.
  • 14 May 2020
    Lipigon enters agreement with HitGen to develop drugs for cardiometabolic diseases
    Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has entered an agreement with STAR listed (Shanghai market) company HitGen Inc. (”HitGen”). The companies will conduct joint research to identify and develop drug candidates that enhance the activity of Lipoprotein Lipase (LPL), with the aim to be used in treatment of lipid disorders and cardiovascular disease.
  • 08 April 2020
    HitGen and MTPC Enter Into License Agreement
    Chengdu, China, April 8, 2020 HitGen Inc. (HitGen) announced today that HitGen and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered into a license agreement to develop a novel class of drugs. This is the second licensing agreement publically announced by the two companies. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing more than 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds.
  • 30 March 2020
    HitGen’s New Generation of NTRK/ROS1 Inhibitor HG030 Approved for Clinical Trial
    On 30th March 2020, HitGen Inc announces that its small-molecule tyrosine kinase inhibitor HG030 has obtained IND approval from the CDE (Center For Drug Evaluation), NMPA, China’s Regulatory Authority for clinical trials and new products approval. The potential indications for HG030 are against the solid tumors harboring NTRK1/2/3/ROS1 fusion genes.
  • 11 March 2020
    HitGen and Kaken Enter Into License Agreement
    Chengdu, China, March 11, 2020 HitGen Inc. (HitGen) announced today that HitGen and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. This is the second licensing agreement. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing over 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of novel small molecule leads for an undisclosed target nominated by Kaken were the subject of this license agreement.

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information